RxDoctor Payments Data

David Schloesser, MD

Neurology · Bend, ORNPI 1750342010

Payments from drug & device makers

$2,246in general payments, 2019–2025

Across 152 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$787
  • AbbVie$349
  • Teva Pharmaceuticals USA, Inc.$186
  • AstraZeneca$154
  • UCB, Inc.$132
  • TG Therapeutics, Inc.$87
  • plus $550 from 22 others

What the payments were for

  • Speaking & faculty fees$452%
  • Food & beverage$2,00089%
  • Education$2019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,246 in reported general payments places this provider in the 60th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$213,699
Medicare patients
483
Services billed
15,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5022$488,536
AustedoDeutetrabenazine14$195,321
TecfideraDimethyl Fumarate14$123,867
Emgality PenGalcanezumab-Gnlm123$90,690
Aimovig AutoinjectorErenumab-Aooe49$50,107
Nurtec OdtRimegepant Sulfate13$31,204
Lacosamide200$20,379
Levetiracetam128$6,680
Memantine Hcl175$5,330
Carbidopa-Levodopa ErCarbidopa/Levodopa64$4,907
Gabapentin293$4,309
Carbidopa-LevodopaCarbidopa/Levodopa174$4,210
AmantadineAmantadine Hcl52$3,683
Lamotrigine225$3,415
Primidone73$2,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$186$195,32114 claims
BiogenTecfidera$787$123,86714 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$27$1,83923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 228 neurology providers in Oregon.

Other neurology in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →